NL-OMON26944
Not yet recruiting
Not Applicable
SOM230 Graves Orbitopathy pilot trial.
Academic Medical Center Amsterdam0 sites12 target enrollmentStarted: TBDLast updated:
ConditionsGraves Orbitopathy
Overview
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Academic Medical Center Amsterdam
- Enrollment
- 12
Overview
Brief Summary
Optimal management of Graves orbitopathy: a multidisciplinary approach. Soeters MR, van Zeijl CJJ, Boelen A, Kloos R, Saeed P, Vriesendorp TM, et al. The Netherlands journal of medicine. 69(7):302–8.
Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G; European Group on Graves' Orbitopathy. J Clin Endocrinol Metab. 2012 Dec;97(12):4454-63.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1\. Moderate – severe GO;
- •2\. Corticosteroids contraindicated due to diabetes mellitus, severe osteoporosis, heart failure, psychosis, infectious diseases or other clinical relevant comorbidities;
Exclusion Criteria
- •1\. Inability/refusal to give informed consent;
- •2\. Pregnancy;
Investigators
Similar Trials
Withdrawn
Not Applicable
SOM230 Graves Orbitopathy pilot trialGraves Orbitopathy/Eye Disease1004373910003816NL-OMON38562Academisch Medisch Centrum12
Recruiting
Not Applicable
Pilot study of SOM230 for Treatment of Graves’ OphthalmopathyDiseases of the eye and adnexaKCT0001645Yonsei University Health System, Severance Hospital20
Completed
Not Applicable
Sirolimus in Graves' OrbitopathyGraves OphthalmopathyNCT05345119University of Pisa30
Not yet recruiting
Phase 2
Sirolimus for Graves' Orbitopathy (GO)Graves OphthalmopathyNCT04598815University of Pisa54
Not yet recruiting
Phase 3
A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 StudyGraves' OrbitopathyNCT05049603University of Pisa102